Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum/taxoid-based neoadjuvant therapy with EGFR or PD-L1 antibody for recurrent resectable head and neck squamous cell carcinoma
ChiCTR2600118681Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Feb 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel, cisplatin, pembrolizumab and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Hunan Cancer Hospital. Primary endpoint: Overall survival at 2 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600118681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118681.